Market Intelligence, Clinical Progress, and High-Purity Reagents for GABAergic Modulation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ABAT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ABAT Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW ~53 kDa. PLP cofactor compatible. |
View ABAT Products |
| Gene Delivery | ABAT Lentivirus Particles Full-length ORF with mitochondrial targeting sequence for stable cell lines. HEK293 Expressed. |
View ABAT Products |
| Benchmark Ab | Anti-ABAT Reference Antibody Sequence Verified recombinant control for Western/IP. |
View ABAT Products |
| Validator | ABAT siRNA Set For knockdown verification and specificity controls. |
View ABAT Products |
| Downstream Target | ALDH5A1 (SSADH) Succinic semialdehyde dehydrogenase - GABA shunt pathway partner |
View ALDH5A1 Products |
| Synthetic Enzyme | GAD1 Glutamate decarboxylase 1 - GABA synthesis enzyme for pathway balance studies |
View GAD1 Products |
| Transporter | SLC6A1 (GAT-1) GABA reuptake transporter - complementary synaptic modulation target |
View SLC6A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Screening (PLP-dependent) | High-purity (>95%) recombinant ABAT with verified cofactor binding site integrity; Spectrophotometric assay compatible |
| Selectivity vs. Off-target Aminotransferases | Ortholog panel available: AGXT, GPT (ALT), GOT1/2 (AST) for cross-reactivity profiling; Sequence Verified |
| Mitochondrial Localization Studies | Lentivirus with native MTS (mitochondrial targeting sequence) for confocal colocalization assays |
| Blood-Brain Barrier Penetration Models | Human/Cyno/Mouse ABAT ortholog proteins available for species cross-reactivity evaluation |
| Mechanism of Action Validation | siRNA included for specificity confirmation; Vigabatrin-resistant mutant constructs available |
Live ABAT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic modulation of ABAT (4-aminobutyrate aminotransferase, GABA-T) represents a cornerstone of GABAergic therapy. While vigabatrin (irreversible inhibitor) has established the target's clinical validity in epilepsy, current R&D is pivoting toward next-generation inhibitors with improved safety profiles and reversible binding kinetics. The competitive landscape is characterized by a shift from broad GABA elevation strategies to precise metabolic modulation, with emerging interest in ABAT for addiction disorders and neurodegenerative conditions.
The race for ABAT therapeutics is intensifying, with major players shifting focus from traditional irreversible inhibitors to novel small molecules with improved selectivity profiles. As first-generation therapies face tolerability challenges, the next wave of R&D is targeting allosteric modulation and substrate-selective inhibition to minimize off-target effects on other PLP-dependent enzymes.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Irreversible Inhibitors | Sabril (Lundbeck), Generic vigabatrin | Refractory epilepsy, Infantile spasms | Time-dependent inhibition kinetics (Need high-purity recombinant enzyme with stable PLP binding) |
| Reversible Small Molecules | Preclinical biotechs | Epilepsy, Addiction, Anxiety | Rapid equilibrium binding assays (Need WT vs mutant ABAT for resistance profiling) |
| Allosteric Modulators | Academic/Early stage | Neurodegeneration | Conformational stability assays (Need full-length protein with mitochondrial targeting verification) |
| Gene Therapy (Upregulation) | Rare disease programs | GABA-T deficiency | Overexpression validation (Need Lentivirus with quantifiable mitochondrial delivery) |